Legend Biotech (LEGN) Gains from Investment Securities (2020 - 2025)

Legend Biotech has reported Gains from Investment Securities for 6 years, with the latest figure at -$877000.0 in Q3 2025.

• For the quarter ending Q3 2025, Gains from Investment Securities fell 101.42% year-over-year to -$877000.0; the trailing twelve-month figure through Sep 2025 stood at -$19.4 million (down 132.15% YoY), and the FY2023 full-year result was -$663000.0, down 11.8% from the prior year.
• Gains from Investment Securities for Q3 2025 stood at -$877000.0, up from -$30.1 million in the prior quarter.
• The five-year high for Gains from Investment Securities was $61.9 million in Q3 2024, with the low at -$30.1 million in Q2 2025.
• Historically, Gains from Investment Securities has averaged $3.5 million across 5 years, with a median of -$316000.0 in 2021.
• Annual changes were most pronounced in 2021 — Gains from Investment Securities sank 3800.0% — and 2022, when it jumped 3374.36%.
• Legend Biotech's Gains from Investment Securities stood at $40000.0 in 2021, then sank by 1582.5% to -$593000.0 in 2022, then retreated by 11.8% to -$663000.0 in 2023, then plunged by 408.9% to -$3.4 million in 2024, then surged by 74.01% to -$877000.0 in 2025.
• The last three Gains from Investment Securities figures came in at -$877000.0 (Q3 2025), -$30.1 million (Q2 2025), and $15.0 million (Q1 2025), per Business Quant data.